share_log

EyePoint Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Elston George

SEC ·  May 29 10:38
Summary by Futu AI
George Elston, the Chief Financial Officer of EyePoint Pharmaceuticals, completed a transaction involving the company's common stock on May 25, 2024. Elston exercised options to acquire 7,500 shares at no cost and subsequently sold 3,627 shares at a price of $11.16 per share. The sale resulted in a total market value of $40,477.32. Following these transactions, Elston's direct holdings in EyePoint Pharmaceuticals common stock amounted to 47,480 shares.
George Elston, the Chief Financial Officer of EyePoint Pharmaceuticals, completed a transaction involving the company's common stock on May 25, 2024. Elston exercised options to acquire 7,500 shares at no cost and subsequently sold 3,627 shares at a price of $11.16 per share. The sale resulted in a total market value of $40,477.32. Following these transactions, Elston's direct holdings in EyePoint Pharmaceuticals common stock amounted to 47,480 shares.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.